ABU DHABI, UAE, May 21, 2024 /PRNewswire/ -- The Department
of Health – Abu Dhabi (DoH), the
regulator of the healthcare sector in the Emirate, signed a
Memorandum of Understanding (MoU) with Roche Pharmaceuticals Middle
East during Abu Dhabi Global Healthcare Week (ADGHW). Under the
MoU, the two entities will advance critical research using
real-world data to study and assess the spinal muscular atrophy
burden in Abu Dhabi, as well as
assessing potential conduction of research and the facilitation of
real-world data collection to monitor Duchenne Muscular Dystrophy
(DMD) disease.
In the presence of Dr. Rashed
Alsuwaidi, the Executive Director of the Healthcare
Workforce Planning Sector at DoH and Michael Oberreiter, Head of Global Access at
Roche Pharmaceuticals, the MoU was signed by Dr. Asma Al Mannaei, the Executive Director of the
Research and Innovation Centre at DoH and Mohamed Elshaarawy, General Manager Roche
Pharmaceuticals, UAE.
Dr. Asma Ibrahim Al Mannaei,
Executive Director of the Research and Innovation Center at the at
DoH said: "Abu Dhabi has a
track record of excellence and fast-growing, future-forward,
data-enabled services. Serving as a hub for healthcare data,
Abu Dhabi's substantial computing
power enables it to harness the potential within this data,
transforming it into valuable information. This, in turn, allows us
to innovate and develop novel approaches to shift healthcare
towards prediction, prevention, and treatment, thereby accelerating
the future of healthcare, not only for Abu Dhabi but for the global community.
Through international collaborations, Abu
Dhabi seeks to lead research groups supported by global
partners to explore the resilience and sustainability of the
healthcare sector worldwide as well as expand access to quality
care for patients around the world."
The two entities will work together to support the evolution of
real-world data collection frameworks in Abu Dhabi. Enhancing DoH's ability to track
and monitor outcomes of therapies will support DoH in making
informed clinical and policy decisions for better optimisation of
patient outcomes. Furthermore, DoH and Roche will strengthen the
research network across Abu Dhabi
and improve accrual for potential clinical trials.
Mohamed Elshaarawy, General
Manager Roche Pharmaceuticals, UAE said: "This MoU
underscores our collaboration with the DoH which is fuelled by a
shared vision of harnessing the power of data to drive informed
decision-making within the healthcare system. Data-driven
healthcare systems hold immense potential to revolutionise patient
care and outcomes. Through the generation, utilisation, and
realisation of data, healthcare professionals and policymakers can
unlock valuable insights, identify trends, and make evidence-based
decisions. This data-driven approach enables us to optimise
resource allocation, personalise treatment approaches, and
ultimately achieve better patient outcomes. By harnessing the full
potential of data, we can improve the overall efficiency and
effectiveness of the healthcare system, ensuring that every patient
receives the highest quality of care tailored to their specific
needs. We are sincerely grateful for the trust, confidence, and
empowerment the DoH has placed in establishing this effective
public-private partnership with Roche in the UAE."
Held under the patronage of His Highness Sheikh Khaled bin Mohamed bin Zayed Al Nahyan, Crown
Prince of Abu Dhabi and Chairman
of Abu Dhabi Executive Council, ADGHW is a major government
initiative by the DoH, which took place from the 13th
-15th May 2024.
For more information please visit: https://www.adghw.com/
About Department of Health – Abu
Dhabi (DoH):
The DoH is the regulatory body of the healthcare sector at the
Emirate of Abu Dhabi and ensures
excellence in healthcare by monitoring the health status of the
population. DoH defines the strategy for the health system,
monitors and analyses the health status of the population and
performance of the system. In addition, DoH shapes the regulatory
framework for the health system, inspects against regulations,
enforce standards, and encourages adoption of world-class best
practices and performance targets by all healthcare service
providers in the Emirate. DoH also drives programmes to increase
awareness and adoption of healthy living standards among the
residents of the Emirate of Abu
Dhabi in addition to regulating scope of services, premiums
and reimbursement rates of the health system.
For further information on DoH,
visit https://www.doh.gov.ae/ and follow on
X, Instagram, Facebook, LinkedIn and YouTube.
Photo -
https://mma.prnewswire.com/media/2417975/DoH_Partners_with_Roche_Pharmaceuticals.jpg
View original
content:https://www.prnewswire.co.uk/news-releases/department-of-health--abu-dhabi-partners-with-roche-pharmaceuticals-middle-east-to-elevate-research-clinical-trials-and-real-world-data-302151316.html